Blinded investigational medicinal product is investigational product whose identity is deliberately concealed within the framework of a blinded clinical trial so that authorized participants cannot recognize the treatment allocation. It comprises not only a similar-looking preparation, but a controlled system of manufacturing, packaging, labelling, randomization, and emergency unblinding. The goal is to maintain the intended blind throughout the entire supply of the study participants.<\/p>\n
Regulation (EU) No 536\/2014 explicitly assigns blinding to the manufacturing of an investigational medicinal product in Article 2(24); according to Article 9 of Delegated Regulation (EU) 2017\/1569, special consideration must be given to the handling of investigational medicinal products during and after the blinding operation. Active study medication, placebo, or other comparator medication must therefore be designed and processed in such a way that the intended persons cannot infer the allocation from the pharmaceutical form, packaging, labelling, or supply route alone. The design depends on pharmaceutical form, administration, risk, and study design.<\/p>\n
Blinding also concerns the assignment of packages to randomization codes. Despite a concealed identity, batches, shelf life, storage conditions, and dispensing must remain traceable. The detailed Commission guidelines C(2017) 8179 final require systems that achieve and maintain the blind, but at the same time allow for the identification of blinded products, including batch numbers, prior to the blinding operation when necessary; the effectiveness of the blinding is to be checked and recorded. Product design must not compromise quality requirements in favor of an externally similar appearance.<\/p>\n
Manufacturing, labelling and supply<\/strong><\/p>\n The manufacturing of blinded investigational medicinal product requires documented operations and a controlled separation of information that could reveal the allocation. Packaging and labelling must comply with regulatory requirements and at the same time reduce the risk of unblinding. In the case of central randomization, individual details on the labelling can be implemented differently; traceability and safe use at the study site nevertheless remain required.<\/p>\n In everyday study practice, storage, shipping, receipt, dispensing, return, and reconciliation with the randomization must be organized in such a way that no unintentional clues arise. Special attention is required for different reconstitution steps, smell or taste, characteristic adverse reactions, and differing packaging sizes. If differences cannot be completely concealed, the protocol and risk analysis must foresee suitable measures, such as separated roles, standardized procedures, or a blinded endpoint assessment.<\/p>\n Emergency unblinding is the regulated disclosure of the identity of a blinded investigational medicinal product if this information is necessary for the medical care of a person. It is not a routine instrument for clarifying organizational questions. The detailed Commission guidelines C(2017) 8179 final require that rapid product identification in an emergency is possible; additionally, Article 14(2) of Delegated Regulation (EU) 2017\/1569 prescribes a procedure for rapid unblinding, applied jointly with the sponsor, if an immediate recall requires this, whereby the identity may only be revealed as far as is necessary. The procedure must define who is allowed to unblind, how the reason is documented, and how access to the information is secured.<\/p>\n The possibility for targeted emergency unblinding must not lift the entire study blind. Randomization code, electronic systems, role authorizations, and documentation must make it possible to provide only the necessary information for the affected person. Following an unblinding, the impact on treatment, safety reporting, data collection, and analysis must be handled according to the pre-specified rules. The protection of the participating person takes precedence over maintaining the blind.<\/p>\n Blinding is the methodological principle according to which one or more parties do not know the treatment allocation. It thus concerns roles and information access in the study, for example participants, investigators, monitors, or evaluating persons. The concrete scope is to be defined in the protocol. It can be single, double, or otherwise designed, without these terms replacing a uniform role list.<\/p>\n Blinded investigational medicinal product, in contrast, is the product- and supply-related implementation of this principle. Through design and controlled processes, it ensures that the allocation does not become apparent from the preparation. A study may require additional blinding measures, such as separated data accesses or independent reviews. Conversely, a blinded product alone is not a complete methodological blinding strategy.<\/p>\n Errors in packaging, labelling, distribution, or code management can unblind individuals or entire teams and thereby compromise the interpretation of efficacy and safety data. A realistic feasibility and risk analysis must therefore connect the pharmaceutical form, the workflows of the study sites, temperature requirements, supply continuity, and the availability of a medically justified emergency unblinding.<\/p>\n Full-service CROs such as Mediconomics support the coordination of protocol, randomization, IMP logistics, and emergency unblinding process. Project management, regulatory affairs, quality management, monitoring, and data management define roles, review the information flow, train study sites, and document dispensing, return, unblindings, as well as their impact on the study data.<\/p>\n Must active preparation and placebo always look completely identical?<\/strong><\/p>\n They must effectively support the intended blind. If differences are not completely avoidable, appropriate additional protective measures are required.<\/p>\n Who is allowed to perform an emergency unblinding?<\/strong><\/p>\n The protocol and the unblinding procedure determine the authorized persons and the documented medical occasion.<\/p>\n Does a single emergency unblinding lift the study?<\/strong><\/p>\n No. The procedure should allow a disclosure limited to the affected person and control the impact on data and analysis.<\/p>\n Blinded investigational medicinal product is investigational product whose identity is deliberately concealed within the framework of a blinded clinical trial so that authorized participants cannot recognize the treatment allocation. It comprises not only a similar-looking preparation, but a controlled system of manufacturing, packaging, labelling, randomization, and emergency unblinding. The goal is to maintain the intended […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6597","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":1,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6597\/revisions"}],"predecessor-version":[{"id":7445,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6597\/revisions\/7445"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6597"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Emergency unblinding and protection of participants<\/h2>\n
Differentiation from blinding as a methodological principle<\/h2>\n
Relevance for clinical trials<\/h2>\n
Frequently Asked Questions (FAQ)<\/h2>\n
Regulatory references<\/h2>\n
\n